CQDM. We celebrate. CQDM celebrates its 15th anniversary. We have some great dates and milestones to highlight and share with you. We start with 2008, the year of the foundation of CQDM. In 2008, the Quebec consortium for drug discovery (CQDM) is founded by Max Fehlmann, with the support and backing of the Fonds de Recherche en…
CQDM. We grow.CQDM is proud to announce the internal promotion of Alexandre Morizot as Director of Business Development. In this new role, Alexandre’s mandate is to create links between companies and university researchers to facilitate and propel collaborative research projects resulting in biopharmaceutical innovations. Along with the CQDM team, he is also actively involved in…
CQDM. We collaborate.CQDM is proud to announce a new collaboration / diffusion / communication partnership with IVADO.We are confident that this new partnership will facilitate biopharma innovation in the Quebec ecosystem and beyond, with a collaborator strongly involved in a complementary sector.IVADO is an interdisciplinary, cross-sectoral research, training and knowledge mobilization consortium whose mission is…
CQDM. We share.The management of the Centre de recherche du CHUM (CRCHUM) invites you to participate in the 14th scientific days which will be held on October 25 and 26, 2023.As part of this unique event, renowned speakers will reveal their most recent scientific advances and their impact on population health.Véronique Dugas, Ph.D., MBA from…
CQDM. We do it.During the breast cancer awareness month, CQDM is proud to announce its participation in the clinical design project for a new targeted and personalized treatment against Sortilin-positive triple negative breast cancers.The research team of Dr. Borhane Annabi at the UQAM | Université du Québec à Montréal, in collaboration with the Theratechnologies Inc.…
Press release: Carole Jabet, Steven Klein and Daria Riabinina join CQDM’s board of directors. MONTREAL, October 11, 2023 – CQDM is proud to announce the appointment of Carole Jabet, Scientific Director at the Fonds de Recherche du Québec en Santé (FRQ-S) and Steven Klein, Chief Business Officer at Epitopea, to its board of directors. Also,…
CQDM. We collaborate.Always with the aim of facilitating and consolidating biopharma innovation in Quebec’s ecosystem and beyond, CQDM is proud to announce a new collaboration / broadcast / communication partnership with Ontario Bioscience Innovation Organization (OBIO).OBIO®, founded in 2009, is a not-for-profit, membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further…
Notice to companies involved in biomanufacturing in Quebec.CQDM, in collaboration with the Quebec government, wishes to improve the biomanufacturing capacity applicable to RNA therapies of companies in Quebec. We need to understand your current service offering and what we could do to improve it.Please complete this short survey before September 29, 2023.Help us help you!…
Challenge: The underlying causes of Alzheimer’s disease (AD) remain poorly understood, and only few dynamic biomarkers are available to monitor responses for experimental therapies. Neuroimaging methods such as structural magnetic resonance imaging (MRI) can detect brain atrophy, but slow changes during disease progression cannot be measured during the timeframe of clinical trials, while functional MRI (fMRI)…
Challenge: One of the major challenges currently faced by the pharmaceutical industry is the development of alternative approaches that allow the gathering of maximum information using a minimum number of animals. With regard to analytical instruments, mass spectrometers offer increasingly sensitive and quantitative determination of biological molecules. However, collected biological samples, especially tissues, require efficient…